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S U M M A R Y
The detection of serum 1,3-b-D-glucan (BDG) has been reported to be useful for the diagnosis and
therapeutic monitoring of various invasive fungal infections. Although Trichosporon fungemia is
increasingly recognized as a fatal mycosis in immunocompromised patients, the utility of this assay for
Trichosporon fungemia is still unknown. In our experience (28 cases), the level of BDG rose in about half
of the patients with hematologic disorders who developed Trichosporon fungemia. Among them, early
death from this infection was more frequently seen in BDG-negative patients than in BDG-positive
patients. In addition, overall survival was also signiﬁcantly worse in BDG-negative patients than in BDG-
positive patients. There were no signiﬁcant differences between these two patient groups in terms of
clinical background. Unlike for other invasive fungal infections, elevation of BDG level may indicate a
paradoxical sign for Trichosporon fungemia in patients with hematologic disorders.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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1,3-b-D-glucan (BDG) is a polysaccharide component speciﬁc to
the fungal cell wall and it circulates in the blood of patients with
invasive fungal infections (IFIs).1 Serum BDG is commonly elevated
in Candida and Aspergillus infections, and may also be elevated,
though this is rare, in infections due to cryptococci and
zygomycetes.2 Therefore, BDG assays have been reported to be
useful for the early diagnosis and therapeutic monitoring of
various IFIs.1–3
Invasive trichosporonosis is an extremely rare mycosis, but has
been increasingly recognized in immunocompromised patients
over the past three decades.4–6 Trichosporon fungemia (TF) is
particularly noted to be a fulminant and highly lethal infection.4–7
However, little data are available on the usefulness of measuring
serum BDG levels in such patients.1,6 We retrospectively evaluated
the clinical signiﬁcance of BDG detection in patients with TF and
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2.1. Patients
We retrospectively reviewed the medical records of 28
consecutive patients with hematologic disorders and TF who
were treated and examined for serum BDG levels at ﬁve
hematology divisions (four belonging to tertiary care hospitals
and one to the Mie University Hospital in Japan) during 2000–
2010. These data were collected and analyzed at the Mie
University Hospital. Patient age ranged from 13 to 85 years
(mean 55 years), and all but one of the patients were male. The
underlying diseases in these patients included acute myeloid
leukemia (20 patients), acute lymphoblastic leukemia (two
patients), chronic myeloid leukemia (two patients), non-Hodg-
kin’s lymphoma (two patients), macroglobulinemia (one patient),
and aplastic anemia (one patient). The Trichosporon species was
identiﬁed on the basis of morphological characteristics, deter-
mined from slide cultures, and biochemical features, determined
using the Vitek yeast biochemical card (bioMe´rieux Vitek Inc.,
Hazelwood, MO, USA) with or without API 20C Aux (bioMe´rieux,
Marcy l’Etoile, France). In most patients, a surveillance culture for
fungi was performed twice a week using throat swab, urine, and
stools specimens. The serum levels of BDG were assayed using the
beta-glucan test WAKO kit (Wako Pure Chemical Industries Ltd,ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Comparison of clinical background in b-D-glucan-positive and b-D-glucan-negative patients
Clinical background BDG-positive (n = 16), n (%) BDG-negative (n = 12), n (%) p-Value
Age >60 years 9 (56) 4 (33) 0.28
Acute leukemia 12 (75) 10 (83) 0.67
Intensive chemotherapy 14 (88) 12 (100) 0.49
Allogeneic HSCT 3 (19) 2 (17) 1.0
Neutropenia 14 (88) 10 (83) 1.0
Neutrophil recovery 5 (31) 1 (8) 0.2
Hyperglycemia 5 (31) 7 (58) 0.25
Candida colonization 6 (38) 8 (67) 0.25
Bacteremia 2 (13) 1 (8) 1.0
Pneumonia 11 (69) 7 (58) 0.45
CVC removal 2 (13) 0 (0) 0.49
G-CSF administration 15 (94) 11 (92) 1.0
Breakthrough infection 14 (88) 11 (92) 1.0
Micafungin related 11 (69) 6 (50) 0.44
Antifungal treatment
Amphotericin B onlya 4 (25) 2 (17) 0.67
Azole only 4 (25) 3 (25) 1.0
Amphotericin B + azole 6 (38) 4 (33) 1.0
Attributable mortality 11 (69) 11 (92) 0.2
Early death within 10 days 6 (38) 11 (92) 0.006
BDG, b-D-glucan; HSCT, hematopoietic stem cell transplantation; CVC, central venous catheter; G-CSF, granulocyte colony-stimulating factor.
a Two patients who received liposomal amphotericin B were included.
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2.2. Infection prophylaxis and empiric therapy
When the neutrophil count was less than 0.5  109/l, most
patients received prophylactic oral antibiotics (ﬂuoroquinolone)
and oral antifungals (ﬂuconazole 200 mg/day, or itraconazole
capsule 100–200 mg/day with amphotericin B 1200–2400 mg/
day), and were housed in rooms equipped with a high-efﬁciency
particulate air ﬁltration system. For patients with a fever higher
than 38 8C, broad-spectrum antibiotics (b-lactam with or without
aminoglycoside, occasionally combined with glycopeptides) were
given as an empiric antibacterial therapy. When high fever
persisted despite the use of these antibiotics for 3 to 5 days,
patients received an empiric antifungal therapy with intravenous
micafungin (100–300 mg/day), amphotericin B (0.5–1 mg/kg per
day), ﬂuconazole (400 mg/day), or miconazole (600 mg/day), or a
combination of these agents (amphotericin B plus a certain azole).
2.3. Deﬁnitions and statistical analysis
A patient was considered to have TF if at least one Trichosporon
species was detected in the blood culture. We detected Trichos-
poron beigelii in 27 samples and Trichosporon pullulans in one
sample. An elevation of serum BDG level was deﬁned as a serum
level higher than 11 pg/ml during the clinical course. Hyperglyce-
mia was deﬁned as a serum glucose level higher than 200 mg/dl,
and renal dysfunction was deﬁned as a serum creatinine level
higher than 2 mg/dl. The manifestation of jaundice was regarded as
liver dysfunction.
Correlations between the two groups were evaluated using
Fisher’s exact test. Patient survival was evaluated by Kaplan–Meier
method, and the difference was evaluated by log-rank test. As all
deaths caused by this infection occurred within 91 days from the
date of diagnosis, the patients who were alive were censored at 100
days after diagnosis; the patients who died from an unrelated
cause, including underlying disease progression, were censored at
the time of death. The statistical signiﬁcance level was deﬁned as a
p-value of <0.05. Data were analyzed using STATISTICA software
(StatSoft, Tulsa, OK, USA).3. Results
Serum BDG was positive in 16 of 28 patients (57%) during the
clinical course. The mean value of its maximum in each of the BDG-
positive patients was 182.5 pg/ml (range 15.0–1471.0 pg/ml).
Clinical features of BDG-positive and the BDG-negative patients
were compared (Table 1). There were no statistically signiﬁcant
differences between the two patient groups in terms of clinical
background, including age, underlying disease, previous intensive
chemotherapy, neutropenia at the onset, neutrophil recovery,
hyperglycemia,6 Candida colonization conﬁrmed by surveillance
cultures,8 bacteremia,9 pneumonia, removal of central venous
catheter, administration of granulocyte colony-stimulating factor,
breakthrough fungal infection, antifungal treatment, and mortality
due to this infection.
Among BDG-positive patients, we assessed the presence of
factors causing false-positive results, such as hemodialysis with
cellulose membrane,10 intravenous albumin, immunoglobulin,11
or certain antibiotics (amoxicillin–clavulanate or piperacillin–
tazobactam),12 or use of glucan-containing gauze.13 One patient
with macroglobulinemia (BDG 75.4 pg/ml) received immunoglob-
ulin, and one with aplastic anemia (BDG 1471.0 pg/ml) received
albumin and was treated with hemodialysis. As for renal and/or
liver failure possibly relating to the elevated BDG levels, renal
dysfunction was observed in one patient with acute myeloid
leukemia (creatinine 2.4 mg/dl, BDG 37.8 pg/ml) and in the patient
with aplastic anemia (creatinine 5.6 mg/dl), who also had liver
failure (total bilirubin 7.2 mg/dl). Breakthrough infection in
patients receiving micafungin,6,7 which is a BDG synthesis
inhibitor,14 was seen in 11 of 16 BDG-positive patients (69%)
and in six of 12 BDG-negative patients (50%). This result did not
indicate that BDG negativity was related to the previous use of
micafungin. The responsiveness to azoles in the treatment of TF has
been reported,6,15,16 but therapy including azoles was performed
at similar frequencies in both BDG-positive patients (10/16, 63%)
and BDG-negative patients (7/12, 58%). However, early death
within 10 days after the onset of TF was more frequently seen in
BDG-negative patients (11/12, 92%) than in BDG-positive patients
(6/16, 38%) (p = 0.006). The overall survival was also noted to be
signiﬁcantly shorter in BDG-negative patients than in BDG-
positive patients (p = 0.029, Figure 1).
Figure 1. Overall survival in patients with Trichosporon fungemia according to the
serum b-D-glucan level. Overall survival was signiﬁcantly longer in patients who
tested positive for b-D-glucan (n = 16) than in those who tested negative for b-D-
glucan (n = 12) (p = 0.029).
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Invasive trichosporonosis is increasingly recognized as a
mycosis with a poor prognosis in patients with hematologic
disorders.4–6 However, there have only been a few reports on the
use of the BDG assay for patients with TF,1,6 and its clinical
signiﬁcance is yet to be ascertained. It has been reported that the
serum concentration of BDG is usually parallel to the amount of
fungal burden in IFIs.1–3,17 However, of note in this study is that
BDG-negative patients had a higher mortality rate (within 10 days)
(p = 0.006) and a worse survival than BDG-positive patients
(p = 0.029). There were no signiﬁcant differences between these
two patient groups in terms of clinical background, supporting a
close relationship between BDG positivity and patient prognosis.
These results are paradoxical ﬁndings, unlike those for other IFIs,
especially for invasive aspergillosis and candidiasis. In trichospor-
onosis, the fungal BDG synthetic system and the relevant host
defense mechanism may differ from those in other IFIs. Additional
studies involving more cases are needed to investigate this issue in
more detail.
As for the possibility of false BDG positivity, the data of two
patients (one with macroglobulinemia receiving immunoglobulin
and one with aplastic anemia receiving albumin and hemodialysis)
may be considered as such results. However, it is unlikely that the
extremely high BDG level (1471.0 pg/ml) in the aplastic anemia
patient could be explained only by factors other than the fungal
burden. Since renal and/or liver function is related to the clearance
and metabolism of the BDG molecule, such organ dysfunction
appears to cause the elevated BDG level. In our series, apart from
the aplastic anemia patient who was treated with dialysis and had
liver dysfunction, one with acute myeloid leukemia displayed a
renal insufﬁciency. However, the above mentioned macroglobuli-
nemia patient and this acute myeloid leukemia patient died 3 days
and 4 days after the onset of TF, respectively. If these two patients
were included in the BDG-negative group, the survival difference
between the two groups would become more distinct.
Some investigators have reported that BDG is recognized by the
innate immune system and plays important roles in host
defense.18,19 Tissue macrophages and dendritic cells are known
to express several BDG receptors including compliment receptor 3,
lactosylceramide, scavenger receptors, and dectin-1;19,20 these
cells resist cytotoxic chemotherapy and retain functional capacity
to protect the body against infection.21,22 In addition, the
administration of BDG has been shown to prevent infection due
to various pathogens.23 Therefore, the anti-infective properties of
BDG may be associated with the better outcome, even in patients
with hematologic disorders. Clariﬁcation of the role of BDG linkedto the host protective system against Trichosporon species may
contribute to the improvement of patient prognosis in this fatal
fungal infection.
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